Lipigon Pharmaceuticals
Lipigon Pharmaceuticals AB is a Swedish clinical-stage pharmaceutical company based in Umeå. It develops medicines for lipid-related diseases, with a focus on disorders of triglyceride and fat metabolism where treatment options are limited or absent.
Fiscal year 2025 · change from previous year
Development 2010–2025
Business
Share of revenueLipisense® is the company's most advanced program, aimed at lowering triglycerides in lipid-related disease.
Human-stage development work for drug candidates targeting lipid-related diseases.
Earlier-stage research programs focused on fat metabolism and related disease mechanisms.
Out-licensing and collaboration arrangements with larger pharmaceutical companies.
Customers
Lipigon does not sell a broad commercial product portfolio; its direct counterparties are mainly pharmaceutical partners, research collaborators, and potential licensees. Its eventual end customers are patients with lipid-related diseases, especially those with high triglycerides, acute pancreatitis risk, or other metabolic and cardiovascular conditions.
Large drug companies that may license Lipigon assets to fund development and commercialization.
Contract research and clinical partners that execute studies and generate development data.
Future end users of Lipisense® and other candidates targeting triglyceride and fat metabolism disorders.
Hospitals, specialists, and payers that would adopt approved therapies if they reach market.
Strategy
Lipigon's strategy is to build a portfolio of lipid-related drug candidates and advance them through clinical development. It seeks to create value either by developing assets itself or by partnering with larger pharmaceutical companies that can fund late-stage development and commercialization.
The lead candidate is the main value driver and the clearest path to clinical proof of concept.
Genetically defined or advanced disease segments can reduce study size and improve signal detection.
Large pharmaceutical partners can provide development funding, sales reach, and regulatory scale.
Geography
Lipigon is headquartered in Umeå, Sweden, with administrative presence also referenced in Stockholm. Its business is research-driven and international in scope because the relevant drug markets include the U.S., Europe, Japan, and other major pharmaceutical markets.
Risks
Lipigon's value creation depends on successful preclinical and clinical development, which is inherently uncertain and can fail even after promising early data. As a small biotech, it is also exposed to key-person dependence, regulatory risk, patent and litigation risk, and competition from larger companies with greater resources.
- Clinical and preclinical failureImpact: HighLikelihood: Medium
Drug candidates can work in early studies but fail in later human trials.
Exposure: Lipisense® and other pipeline projects
- Key-person dependenceImpact: HighLikelihood: Medium
A small clinical-stage company relies heavily on specialized scientific and managerial talent.
Exposure - Regulatory and approval riskImpact: HighLikelihood: Medium
Drug development requires successful regulatory review, and approvals may be delayed or limited.
Exposure: Clinical programs and future market access
- Competitive pressureImpact: MediumLikelihood: Medium
Larger companies can outspend smaller firms in R&D, regulatory work, and commercialization.
Exposure: Lipid disorder treatment market
- Patent and litigation riskImpact: MediumLikelihood: Low
Biopharma companies face disputes over intellectual property and freedom to operate.
Exposure: Drug candidates and partnering value
Accounting
Judgemental itemsThe company states that milestone payments are recognized in the period they are achieved, which can create lumpy revenue.
Impact: Reported revenue may depend on contract events rather than steady sales
The company discloses future lease payments and annual lease expense, which affect fixed cost visibility.
Impact: Useful for assessing cash obligations and overhead
The company has issued share-based instruments, which can affect equity structure and dilution.
Impact: Important for per-share analysis and financing assessment
Accumulated tax losses may create deferred tax assets if future taxable profits emerge.
Impact: Relevant to long-term tax planning and balance sheet valuation
Similar listed companies
Publicly listed companies with a comparable business focus.
Lipocine Inc.
LPCN · Pharmaceutical Preparations
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
PepGen Inc.
PEPG · Pharmaceutical Preparations
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
Aligos Therapeutics, Inc.
ALGS · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026